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Objective: To study whether isolated tumor cells and micrometastases, as defined by
the current American Joint Committee on Cancer criteria for extrapulmonary
neoplasms, have prognostic value for patients with resected non–small cell carci-
noma of the lung.
Methods: Intrathoracic lymph nodes (n  1063) from 60 patients with non–small
cell carcinoma of the lung were studied for the presence of metastases with serial
histologic sections and keratin immunostains. Metastases were classified as isolated
tumor cells, pN1mi, pN1, pN2mi, and pN2. Isolated tumor cells were smaller than
0.2 mm, while pN1mi and pN2mi measured 0.2 mm to 2 mm. Survival analysis was
performed, stratifying by nodal status and stage.
Results: Isolated tumor cells were detected in 11 lymph nodes from 5 of 33 pN0
patients and in 9 pN1 and pN2 patients. The lymph nodes from 3 patients were
reclassified as pN1mi. No pN2mi were detected. A survival model based on a
stratification of the cohort into stages I to III was significant (chi-square 7.426, df
 2, P  .024) but demonstrated considerable overlap between the survival curves
of stage I and II patients. A model stratifying isolated tumor cells and pN1mi into
stage I disease was significant (chi-square  7.985, df  2, P  .018) and showed
no overlap between the survival curves of stage I and II patients. There were no
significant survival function differences between patients with pN0, isolated tumor
cells, and pN1mi.
Conclusions: Patients with non–small cell carcinoma of the lung with isolated tumor
cells and pN1mi have similar survivals to those with pN0, consistent with the
findings reported for breast cancer patients. Future larger studies of patients with
non–small cell carcinoma of the lung are needed to confirm whether current
American Joint Committee on Cancer staging criteria should be modified to include
the pN1mi category.
The American Joint Committee on Cancer (AJCC) has recently pub-lished the sixth edition of the AJCC Cancer Staging Manual, includ-ing revised staging criteria for breast, colon, and other neoplasms.1Staging criteria for lung cancer remain unchanged. The evaluation ofthe lymph node status of patients with non–small cell lung cancer(NSCLC) has been a source of controversy.2,3 Lymph node metas-
tases can be subclassified into intranodal growth when the tumor is confined within
the lymph node capsule and extranodal growth when there is neoplastic invasion of
the soft tissues surrounding the nodal tissues. However, as demonstrated by Bollen
and associates,4 it is seldom feasible to classify, on the basis of mediastinoscopy, a
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lymph node involvement as intranodal or extranodal, as
portions of each lymph node rather than the entire intact
lymph nodes are biopsied. This feature is not used for the
routine staging of NSCLC patients or included in the current
AJCC criteria for lung cancer.
Several studies have detected keratin-immunoreactive
tumor cells in up to 63% of intrathoracic lymph nodes from
NSCLC patients.5-10 The prognostic value of detecting these
“occult metastases” or “micrometastases” in lung cancer
and other neoplasms is the subject of intense research.5,11-18
Cote and associates3,19-22 indicated that “the accumulated
evidence strongly suggests that the detection of occult re-
gional and systemic metastases is an important predictor of
disease progression.” In a more recent study of 119 patients
with T1, N0, and M0 adenocarcinoma and bronchioloalveo-
lar carcinoma of the lung, Goldstein and associates12 re-
ported “micrometastases” detectable by keratin immunohis-
tochemistry in up to 8% of N0 patients. However, the
overall sensitivity of the method was low, and positive cells
were detected in only 0.5% to 1% of the lymph nodes
examined. In one of their groups of patients who developed
metastatic disease, the finding of micrometastases was sig-
nificant for prognosis by multivariate analysis, but the au-
thors concluded that due to the low sensitivity of the detec-
tion method, the use of immunohistochemical screening of
lymph nodes for all N0 patients is questionable. Their study
also confirmed the prognostic value of pathologic features
such as vascular invasion, extensive central fibrosis, and
high nuclear grade. Similar problems have been reported in
studies of patients with esophageal, breast, and other neo-
plasms.5,11,14,23-27
The new AJCC Cancer Staging Manual proposes im-
proved terminology for the classification of lymph node
metastases. Isolated tumor cells (ITC) are defined as single
tumor cells or small clusters of cells, smaller than 0.2 mm in
greatest diameter.1 ITC can be seen on routine hematoxylin
and eosin (H&E) stained sections (pNOi, pNOmol) or
detected with the aid of immunohistochemistry (pNOi) or
molecular methods (pNOmol). Micrometastases are clus-
ters of tumor cells measuring between 0.2 mm and 2 mm in
greatest diameter; they can usually be detected with routine
histology and are classified as pN1mi or pN2mi according
to their location. However, according to current AJCC cri-
teria for lung cancer, NSCLC patients with a few intranodal
tumor cells detected by routine histology or immunohisto-
chemistry should be categorized as pN1 or pN2 according to
their location. To our knowledge, it is unclear whether these
patients have a similar prognosis as those with larger nodal
metastases. We studied the prognostic value of detecting
ITC in intrathoracic lymph nodes and distinguishing pN1mi
and pN2mi from pN1 and pN2 in a group of 60 consecutive
NSCLC patients who had long-term clinical follow-up.
Methods
NSCLC patients treated with lobectomy at Cedars-Sinai Medical
Center during an arbitrarily selected 2-year period (July 1993 to
June 1995) were studied. Sixty consecutive patients had adequate
clinical follow-up information available at our Tumor Registry.
Our Institutional Review Board approved the study and proper
informed consent guidelines were followed. Patients who survived
the disease had a minimum 5-year clinical follow-up after the
initial treatment. The cohort included 37 women and 23 male
patients, ranging in age from 37 to 94 years (66.72 12.42 years).
NSCLC cell types included adenocarcinoma (n  37), squamous
cell carcinoma (n  10), adenosquamous carcinoma (n  9), and
large cell carcinoma (n  4). Tumors ranged in size from 1.6 cm
to 10 cm in greatest dimension (4.11  1.53 cm). The pT infor-
mation of the neoplasms included: pT1  19, pT2  32, pT3  3,
and pT4  6 cases. The initial nodal status of the 60 patients was:
pN0  33, pN1  11, and pN2  16. The H&E-stained histologic
slides from 1063 formalin-fixed, paraffin-embedded intrathoracic
lymph nodes from these patients were reviewed. Two serial sec-
tions, 4 m in thickness, were made from each lymph node at
50-m intervals and stained with H&E. A third serial section from
each lymph node was stained with immunohistochemistry for
keratin AE1/AE3 (Chemicon Inc, Temecula, Calif), using a stan-
dard DAKO Envision peroxidase method (DAKO, Carpinteria,
Calif). A working dilution of 1:2000 was used for the primary
antibody. Our experience with NSCLC is similar to that of Cote
and associates,19 who have demonstrated that keratin AE1 and
CAM 5.2 yield similar results for the detection of lymph node
metastases in breast cancer patients.
Estimation of Nodal Status
Based on the examination of the initial histologic slides, the initial
nodal status of each patient was recorded. The lymph nodes were
classified as pN0, pN1, and pN2 according to current AJCC
criteria for NSCLC. The size of all lymph node metastases was
measured with an eyepiece micrometer. The size of all metastases
from the various lymph nodes from each patient was added to an
aggregate tumor size per case and stratified into 3 categories:
smaller than 0.2 mm, 0.2 mm to 2 mm, and larger than 2 mm. ITC
detected in H&E-stained serial histologic sections were classified
as pNOi. They consisted of single or small groups of cells with
cytologic features including a nuclear size larger than the diameter
of 3 resting mature lymphocytes, anisocytosis, macronucleoli,
irregular nuclear membranes, and/or high nucleo:cytoplasmic ra-
tio. Cells with cytoplasmic keratin immunoreactivity that exhibited
similar cytologic features, visible with the aid of the nuclear
counterstain, were classified as pNOi. The N status of each case
was reclassified into 6 ordered categories, using the terminology
proposed in the sixth edition of the AJCC cancer staging manual
for breast cancer and other neoplasms: pN0, ITC (including
pNOi and pNOi), pN1mi, pN1, pN2mi, and pN2. Figures 1
and 2 show examples of isolated tumor cells and micrometastases.
Statistical Analysis
Survival functions were estimated using the Kaplan-Meier method.
Survival functions were compared across current N criteria (pN0,
pN1, and pN2) and enhanced criteria including ITC and pN1mi as
additional categories. Survival functions of pN0 patients were
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compared with those with ITC and pN1. Survival functions of
patients with ITC and pN1mi were compared with those with pN1.
Survival functions were also analyzed by stage, stratifying patients
into stages I to III, and by a modified staging scheme that included
patients with ITC or pN1 in the stage I group. Homogeneity of
survival functions was analyzed using the log-rank test (Mantel
method). Analyses were performed using Systat 10.0 software
(SPSS Science, Chicago, Ill). Regression analysis was performed
to compare the tumor size with the presence of isolated tumor cells
in pN0 patients.
Results
Nine hundred forty lymph nodes (88.4%) were negative for
metastatic tumor, and 123 lymph nodes (11.6%) were pos-
itive by examination of the initial H&E-stained slides. ITC
were encountered with the aid of immunohistochemistry in
11 of 463 (2.4%) lymph nodes originally classified as pN0;
the same ITC were also visible by examination of H&E-
stained step sections in 5 of those lymph nodes. Lymph
nodes with pNOi and pNOi were encountered in 5 of 33
(15.2%) pN0 patients (Table 1). Regression analysis
showed no significant relationship between tumor size and
the presence of isolated tumor cells and/or micrometastases
in pN0 patients (df  1, F  0.026, P  .87).
In addition, ITC were encountered in 9 of 477 (1.9%)
previously negative lymph nodes from pN1 and pN2 cases.
None of the pN1 patients were upstaged to pN2 as a result
of encountering ITC. The lymph nodes from 3 of 11
(27.3%) patients with pN1 nodal status by initial examina-
tion had metastases measuring 0.2 mm to 2 mm in greatest
diameter and could be reclassified as pN1mi. All cases with
pN2 had metastases larger than 2 mm.
The proportions of patients who survived their disease,
by nodal status, are shown in Table 1. The survival propor-
tions of pN0 cases (63.6%) did not change after ITC cases
Figure 2. Photomicrograph of a lymph node with metastatic ad-
enocarcinoma. The tumor nodule is smaller than 2 mm in diam-
eter, the cutoff diameter used for the diagnosis of micrometasta-
ses. A lymph node with these cells is classified as pN1mi.
TABLE I. Survival proportions of non–small cell carcinoma
of the lung patients, by nodal status classified with differ-
ent criteria (n  60)
Criteria for
classification of nodal
status Nodal status
Total number
of patients
Number of
patients who
survived 5 years
Current AJCC criteria
for lung cancer
patients
pN0 33 21 (63.6%)
pN1 11 5 (45.4%)
pN2 16 3 (18.8%)
AJCC criteria
proposed for
breast cancer and
other neoplasms
pN0 28 18 (64.3%)
Isolated tumor
cells
5 3 (60%)
pN1mi 3 3 (100%)
pN1 8 2 (25%)
pN2 16 3 (18.8%)
Figure 1. Photomicrograph of isolated tumor cells in a lymph
node from a patient with adenocarcinoma of the lung (Dako
Envision peroxidase method, 400). A few cells with cytoplasmic
keratin immunoreactive are present near the subcapsular sinus of
a lymph node. The inset shows that the cells have a size that is
approximately 3 times the size of normal lymphocytes. A lymph
node with these cells is classified as pN0i to indicate the
presence of isolated tumor cells detectable with immunohisto-
chemistry.
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were removed from this group and reclassified as pN0i
(64.3%). The survival proportions of pN1 patients declined
considerably from 45.4% to 25% after cases with microme-
tastases were removed from this group and reclassified as
pN1mi. All 3 patients with pN1mi survived. Figure 3 shows
significantly different survival curves by initial nodal status
(chi-square  7.744, df  2, P  .021). There were no
significant differences in the survival functions of pN0
patients compared with those with ITC and pN1mi (chi-
square  0.001, df  1, P  .975). Figure 4 shows no
significant differences in the survival functions of patients
with pN0i or pN1mi compared with those with pN1
(chi-square 3.028, df 1, P .082). However, the graph
shows 2 distinct survival curves and the lack of significant
differences may result from the small sample size. Survival
functions could not be compared across the pN1 and pN1mi
categories due to the small number of patients. Figure 5
shows different survival curves for patients stratified by
stages I to III (chi-square  7.426, df  2, P  .024).
However, this model shows some overlap between the sur-
vival curves of stage I and II patients. Figure 6 shows
different survival curves by stage when cases with ITC and
pN1mi are classified as stage I disease (chi-square  7.985,
df  2, P  .018). This model shows a distinct survival
curve for stage I disease and some overlap between the
survival curves of stage II and III disease.
Discussion
Our preliminary study suggests that the current criteria
proposed by the AJCC for the classification of the N status
of various extrapulmonary neoplasms may also be useful for
NSCLC patients. We detected ITC in 15.2% of pN0
NSCLC patients, but this finding did not influence the
proportion of pN0 patients who survived their disease or
their survival functions. Our results support the use of
pNOi and pNOi, rather than pN1, terminology for pa-
tients with ITC until more data are available to justify
staging them as stage II disease. Similar findings have been
reported in studies of breast cancer and other neoplasms,
leading to the development of the current pNOi, pNmi
terminology supported by AJCC.1 Our data, based on a very
small number of cases, also suggest that measuring the size
of small lymph node metastases and classifying them into
pN1mi, using the 2-mm cutoff value proposed by AJCC for
other neoplasms, may have a prognostic value in NSCLC
patients. Patients with pN0i and pN1mi had 60% and
100% survivals, respectively, compared with a 25% sur-
vival for patients with metastases larger than 2 mm in pN1
lymph nodes. Moreover, the survivals of patients initially
classified as pN1 declined from 45.4% to 25% after the 3
cases with micrometastases were excluded. Survival analy-
sis by stage, classifying NSCLC patients with ITC and
pN1mi as stage I rather than stage II disease, yields a
significant survival model and appears to provide distinct
survival curves between stage I and others.
The study of lymph nodes with immunohistochemistry
and the measurement of metastases did not contribute sig-
nificant prognostic information to our pN2 patients. No
instances of pN2mi were encountered in our 16 pN2 pa-
tients, and none of our 11 pN1 patients were upstaged as a
result of these additional studies. These findings suggest
that keratin immunohistochemistry is unlikely to be useful
for the study of larger cohorts of pN1 and pN2 patients.
Future studies with larger number of pN1 cases are needed
to confirm the possible prognostic value of identifying
pN1mi.
Figure 4. Survival analysis of a subgroup of 16 patients, showing
apparent, but no significant differences in survivor function be-
tween patients with isolated tumor cells (ITC) and micrometas-
tasis (pN1mi) from those with nodal metastases larger than 2 mm
in size.
Figure 3. Survival analysis of all 60 patients showing significant
stratification of the patients by the original nodal status.
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Our study raises questions regarding the practical role of
immunohistochemistry for the study of lymph node metas-
tases in patients with NSCLC. Several previous studies have
reported that the finding of keratin immunoreactive tumor
cells in approximately 4% to 63% of lymph nodes from
NSCLC patients is usually associated with a less favorable
prognosis.5-8,10,28,29 However, various definitions for “mi-
crometastases” or “occult metastases” have been used; the
size of the metastases has not always been reported and
relatively small numbers of patients have been studied.30-32
Potential sources of variability include the study of only N0
patients by some investigators and of N0 to N3 by others
and the use of different antibodies and/or immunohisto-
chemical detection methods.12 Our data support the sugges-
tion by Goldstein and associates12 that although ITC can be
detected with immunohistochemistry in a significant num-
ber of previously negative lymph nodes, many of them are
seen in NSCLC patients with other positive pN1 and pN2
lymph nodes. Slightly less than half of the lymph nodes with
immunoreactive ITC encountered in our study were de-
Figure 5. Survival analysis of all 60 patients by stage before correction of nodal status for the presence of microme-
tastases. The graph shows considerable overlap between the survival curves of patients in stages I and II.
Figure 6. Survival analysis of all 60 patients after the stage was corrected by subtracting micrometastases from
the pN1 category. The graph shows visually different curves for patients in stage I and II disease.
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tected in the negative lymph nodes from patients with other
positive pN1 and pN2 lymph nodes; the stage of these
patients remained unchanged.
The influence of the size of intranodal metastases on the
prognosis of NSCLC patients has not been studied exten-
sively, to our knowledge. Bollen and associates4 demon-
strated that NSCLC patients with “minimal disease,” char-
acterized by the presence of a single, small metastatic focus,
had significantly better survival rates than N2 patients with
more extensive nodal involvement.
Molecular methods may offer a more sensitive and cost-
effective method for the detection of occult micrometastases
in the future, but it is unclear if these findings are going to
provide prognostic information for NSCLC patients. Sal-
erno and associates18 demonstrated the presence of MUC1
RNA in histologically negative lymph nodes from NSCLC
patients, using reverse-transcriptase-polymerase chain reac-
tion. Recently D’Amico and colleagues33,34 and Ahrendt
and coworkers35 have applied molecular methods to the
assessment of lymph nodes in patients with resected stage I
NSCLC. Occult lymph node metastases identified based on
the presence of p53 and k-Ras mutations are found in up to
50% of patients but do not correlate with overall survival.35
D’Amico and colleagues33,34 have demonstrated that ex-
pression levels of markers such as p53, urokinase plasmin-
ogen activator, E-cadherin, and ErbB2 correlated with the
rate of brain metastases.
It is premature to speculate how stage I and II NSCLC
patients will be managed in the future based on the detection
of micrometastatic disease, as current postoperative thera-
peutic modalities are not very effective. To our knowledge,
breast cancer patients with micrometastases are currently
not being treated with chemotherapy, although this option is
offered to pN1 patients.19
In conclusion, NSCLC patients with ITC and pN1mi
have similar survival rates as those with pN0, results that are
consistent with those already reported for breast cancer and
other cancer patients. Lymph nodes with ITC should prob-
ably not be classified as pN1 until future studies demon-
strate a clear prognostic value for this finding. Larger groups
of NSCLC patients with stage II disease need to be studied
for the distinction of pN1mi versus pN1 to determine
whether current AJCC staging criteria for NSCLC patients
need to be modified.
The authors thank Dr Randa Alsabeh for assistance in the
performance of immunostains and the selection of cases.
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